The DOI matches its Crossref record; 437 of the 445 references it cites were found in a registry or an index; none of the 187 sources its claims cite is checked for support yet.
Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications
Open accessAbstract
Mounting evidence indicates that inflammatory cytokines contribute to the development of depression in both medically ill and medically healthy individuals. Cytokines are important for development and normal brain function, and have the ability to influence neurocircuitry and neurotransmitter systems to produce behavioral alterations. Acutely, inflammatory cytokine administration or activation of the innate immune system produces adaptive behavioral responses that promote conservation of energy to combat infection or recovery from injury. However, chronic exposure to elevated inflammatory cytokines and persistent alterations in neurotransmitter systems can lead to neuropsychiatric disorders and depression. Mechanisms of cytokine behavioral effects involve activation of inflammatory signaling pathways in the brain that results in changes in monoamine, glutamate, and neuropeptide systems, and decreases in growth factors, such as brain-derived neurotrophic factor. Furthermore, inflammatory cytokines may serve as mediators of both environmental (e.g. childhood trauma, obesity, stress, and poor sleep) and genetic (functional gene polymorphisms) factors that contribute to depression's development. This review explores the idea that specific gene polymorphisms and neurotransmitter systems can confer protection from or vulnerability to specific symptom dimensions of cytokine-related depression. Additionally, potential therapeutic strategies that target inflammatory cytokine signaling or the consequences of cytokines on neurotransmitter systems in the brain to prevent or reverse cytokine effects on behavior are discussed.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This review argues that inflammatory cytokines contribute to a subtype of depression by altering neurotransmitter, neuropeptide, growth-factor, and glutamate systems, with evidence drawn from human and animal studies. It proposes that cytokine-related depression may be identified through inflammatory biomarkers and genetic variants and treated by targeting inflammation or its downstream neural effects.
Key findings
- Elevated proinflammatory cytokines and markers—including IL-1, IL-6, TNF-alpha, CRP, and PGE2—are reported in idiopathic major depression and in medically ill populations; cancer patients show elevated cytokines and depression/fatigue rates approaching 50%, and IFN-alpha treatment induces depression in 30–50% of patients depending on dose.
- Peripheral cytokines can reach the brain through circumventricular organs, active transport, vagal afferents, endothelial/perivascular activation, and immune-cell recruitment, then amplify local inflammatory signaling involving COX-2/PGE2, microglia, IDO/KYN metabolites, iNOS, and reactive oxygen/nitrogen species.
- Specific polymorphisms are linked to particular symptom dimensions: IL-6 rs1800795 with depression but not worsening fatigue during IFN-alpha therapy; TNF-alpha A-308G rs1800629 with irritable anger rather than depression; 5-HTTLPR with neurovegetative symptoms; BDNF Met with more psychological/cognitive symptoms; and IDO1 rs9657182 with IFN-alpha-induced depression in Caucasian C-risk-allele carriers but not African Americans.
- Therapeutic implications include SSRIs being more effective for mood, anxiety, and cognitive symptoms than for fatigue/neurovegetative symptoms; the TNF antagonist infliximab improved depressive symptoms in treatment-resistant patients only when baseline CRP was high (hsCRP >5 mg/L); other candidates include COX inhibitors, omega-3 fatty acids, p38 MAPK/NF-kB inhibitors, BH4/monoamine-synthesis support, IDO/KYN inhibitors, and NMDA antagonists.
Methods
- Narrative review synthesizing human clinical studies—including idiopathic major depression, medically ill populations, IFN-alpha-treated patients, CSF and blood biomarker studies, neuroimaging, and genetic association studies—alongside animal and preclinical mechanistic work.
- The paper integrates evidence across proposed pathways: cytokine access to the brain, monoamine and glutamate neurotransmission, BDNF, CRH/HPA-axis function, and inflammatory signaling.
- Main analysis is qualitative synthesis; no systematic search strategy, meta-analysis, or formal risk-of-bias assessment is described.
Limitations
- The paper states that much of the vulnerability and treatment literature relies on correlative relationships among SNPs, inflammatory or neurotransmitter biomarkers, and behavioral symptoms, so mechanistic animal/translational studies and subsequent clinical trials are needed.
- The paper also states that more human neuroimaging is needed, that peripheral transcriptomic findings should be integrated with brain imaging, and that many studies did not examine biomarkers or polymorphisms in relation to specific depressive symptom dimensions.
- Evident from the text: as a narrative review, it lacks a systematic search and inclusion process, and many cited findings come from specific populations or preclinical models, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 187 cited sources checked · 0 supported · 0 flagged
In the paper
“Nonetheless, it is biologically plausible that inflammatory cytokines serve as mediators of both environmental and genetic factors that may trigger the development of depressive disorders (Raison and Miller, 2011).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
What the sources say
- Not checked yetcites Raison and Miller, 2011 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, under conditions of chronic exposure to elevated inflammatory cytokines, persistent alterations in neurotransmitter function and behavior can lead to the development neuropsychiatric dysfunction, and especially depression.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Furthermore, administration of cytokines to humans and laboratory animals produces neuropsychiatric symptoms and behavioral alterations consistent with depression (Miller et al., 2009).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
What the sources say
- Not checked yetcites Miller et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Mounting evidence indicates that inflammatory cytokines contribute to the development of depression in both medically ill and medically healthy individuals.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Cytokines also have the capability of influencing neurocircuitry and neurotransmitter systems to produce behavioral alterations (Miller et al., 2009, Haroon et al., 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Numerous studies have reported increases in circulating proinflammatory cytokines, interleukin (IL)-1, IL-6, tumor necrosis factor (TNF)-alpha, their soluble receptors, and the acute phase protein, C-reactive protein (CRP), in patients with idiopathic major depression (Maes et al., 1992, Maes, 1999, Sluzewska, 1999).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.1 Elevated cytokines and inflammatory markers in idiopathic major depression
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, depression that is associated with inflammatory cytokines may be one subtype of depression.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Acutely, administration of cytokines or activation of the innate immune system can induce a behavioral repertoire termed “sickness behavior” that includes anhedonia, anorexia, fever, sleep changes, and decreased social interaction (Dunn and Swiergiel, 1998, Dunn et al., 2005, Dantzer and Kelley, 2007).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“some patients with idiopathic major depression without co-morbid medical illness also exhibit increased circulating cytokines and inflammatory markers (Maes et al., 1992, Maes, 1999, Sluzewska, 1999, Dowlati et al., 2010).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“However, it is worthy to note that one study observed no association between the development of IFN-alpha-induced depression and polymorphic regions examined in the genes encoding TNF (rs1799964, rs1800629, rs3093662, rs769178), IL6 (rs1800795, rs1800796, rs1800797), IL1A (rs3783516, rs3783546), IL1B (rs1143643, rs1143644, rs16944, rs4848306), chemokine MCP-1/CCL2 (rs1024611, rs2530797,rs4586), or”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.6 Genetic vulnerability to exogenous cytokine-induced depression
What the sources say
- Not checked yetcites Smith et al., 2012 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- Probably not a substantial claim. 3
- It may state two separate claims as one. 53
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We should note that not all types of depression necessarily involve cytokines, e.g. post-partum and peri-menopausal depression, hypothyroidism, depression secondary to cocaine withdrawal, and vascular depression to name just a few.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“That is, not all subjects exhibiting increased inflammatory cytokines develop depression, and there are numerous vulnerability and resilience factors for cytokine-induced depression (Kendler et al., 2001, Caspi et al., 2003, Duman and Monteggia, 2006, Heim et al., 2008, Lotrich, 2011)”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Factors that may precipitate inflammation and influence the development of depression include medical illness, obesity, psychosocial stress, sleep disturbance, and gastrointestinal inflammation, and will be discussed herein.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 1. Introduction
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Interestingly, all of these pathways have been demonstrated to be affected by inflammatory cytokines (Pace et al., 2007, Dantzer et al., 2008, Miller et al., 2009, Haroon et al., 2012) (Figure 1).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Consistent with the relationship between circulating IL-6 and IFN-alpha-induced depression, a functional polymorphisms in the promoter region of the IL-6 gene (rs1800795), the genotype that produces more IL-6, was found to be associated with depression but not the fatigue that worsens during IFN-alpha therapy (Bull et al., 2008).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.6 Genetic vulnerability to exogenous cytokine-induced depression
What the sources say
- Not checked yetcites Bull et al., 2008
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, cancer patients exhibit elevated circulating proinflammatory cytokines and develop depression and fatigue at rates approaching 50% (Musselman et al., 2001b, Massie, 2004, Jehn et al., 2006).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.2 Medical illness and depression
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“IFN-alpha is notorious for producing behavioral symptoms including fatigue and neurovegetative symptoms, cognitive and sleep changes, anxiety, and anhedonia, and induces depression in 30–50% of treated-patients depending on the dose (Capuron et al., 2002, Maddock et al., 2005, Raison et al., 2005a, Lotrich, 2009).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.5 Exogenous cytokine administration and depression
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Interestingly, omega-3 fatty acids are reduced in major depression and also predict vulnerability to cytokine-induced depression (Su et al., 2010, Lotrich et al., 2012, McNamara and Lotrich, 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.6 Genetic vulnerability to exogenous cytokine-induced depression
What the sources say
- Not checked yetcites Su et al., 2010
- Not checked yetcites Lotrich et al., 2012
- Not checked yetcites McNamara and Lotrich, 2012
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Therefore, DAMPS and the NLRP3 inflammasome may serve as a primary link by which chronic psychological or physical stress is translated into damage signals that promote inflammatory activity, and may contribute to depression as well as associated co-morbid medical illnesses related to chronic stress (Iwata et al., 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.3 Sources of cytokines and inflammation in medically healthy individuals
What the sources say
- Not checked yetcites Iwata et al., 2012
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Inflammatory cytokine administration and low-grade chronic inflammation have been shown to increase IDO activity and the metabolisms of tryptophan, the primary amino-acid precursor of serotonin, to KYN in the periphery (Capuron et al., 2003a, Raison et al., 2010b, Capuron et al., 2011a).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Capuron et al., 2003a
- Not checked yetcites Raison et al., 2010b
- Not checked yetcites Capuron et al., 2011a
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Finally, obesity is associated with increased circulating cytokines, and BMI significantly influences concentrations of L-6 and other inflammatory markers (Khaodhiar et al., 2004).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.3 Sources of cytokines and inflammation in medically healthy individuals
What the sources say
- Not checked yetcites Khaodhiar et al., 2004 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Interestingly, selective serotonin (5-HT) reuptake inhibitors (SSRIs) have been shown to alleviate cytokine-induced depression (Musselman et al., 2001a, Raison et al., 2007), and depressive and anxiety symptoms appear to be most responsive, while fatigue and neurovegetative symptoms are less responsive (Capuron et al., 2002, Raison et al., 2005b, McNutt et al., 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.6 Genetic vulnerability to exogenous cytokine-induced depression
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In the brain, IDO activity is significantly increased at 24 hr and peaks at 48 hr in response to LPS administration, corresponding to the expression of some depressive-like behaviors, e.g. increased immobility in the forced-swim and tail suspension tests, in laboratory animals (Lestage et al., 2002, O'Connor et al., 2008).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Lestage et al., 2002 source
- Not checked yetcites O'Connor et al., 2008
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These finding suggest that neuroactive KYN metabolites, KA and QUIN, are likely responsible for many behavioral changes associated with cytokine-induced IDO activity, and may involve effects on other neurotransmitter systems (see Section 3.3 for discussion).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Interestingly, inflammatory cytokines, including IL-6, have been shown to increase 5-HTT expression and function (Morikawa et al., 1998, Mossner et al., 1998, Sakai et al., 2003, Tsao et al., 2008) (see Figure 1), an effect found to be mediated by induction of p38 mitogen-activated protein kinase (MAPK), both in vitro and in vivo (Zhu et al., 2005, Zhu et al., 2006, Zhu et al., 2010a).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In terms of immunologic mechanisms of IFN-alpha-induced depression, IFN-alpha may act directly on the central nervous system (CNS), but may also exert indirect effects via the activation of other peripheral and central inflammatory cytokines (Raison et al., 2009).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.5 Exogenous cytokine administration and depression
What the sources say
- Not checked yetcites Raison et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Interestingly, a polymorphism (rs9657182) in the promoter region of the gene encoding IDO1 was found to be associated with IFN-alpha-induced depression in Caucasian subjects homozygous for the C risk allele, but not African Americans who exhibited a markedly lower frequency of the risk allele at this locus (Smith et al., 2012)(see Table 1 for details).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.6 Genetic vulnerability to exogenous cytokine-induced depression
What the sources say
- Not checked yetcites Smith et al., 2012 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“These metabolites can then interact with neurotransmitter systems in the brain, particularly glutamate (see Section 3.3), and are thought to be involved in the behavioral effects of cytokines (Dantzer et al., 2011, Haroon et al., 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.6 Genetic vulnerability to exogenous cytokine-induced depression
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In patients treated chronically with IFN-alpha for hepatitis C virus (HCV), CSF concentrations of IL-6 negatively correlated with 5-HIAA concentrations, which in turn negatively correlated with IFN-alpha-induced depression severity (Raison et al., 2009).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Raison et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Cytokines released by peripheral immune cells or adipose tissue can access the CNS to initiate local immune activation by several mechanisms, including 1.) passage through leaky regions in the blood-brain-barrier at circumventricular organs”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.4 Access of peripheral cytokines to the brain and activation of local inflammatory networks
What the sources say
- Not checked yetcites Katsuura et al., 1990
- Not checked yetcites Banks et al., 1995 source
- Not checked yetcites Bluthe et al., 1994
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Another source of inflammatory cytokines is the gut, and there has been attention paid to the role of intestinal microorganisms in influencing the immune responses of an organism (Lee and Mazmanian, 2010).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.3 Sources of cytokines and inflammation in medically healthy individuals
What the sources say
- Not checked yetcites Lee and Mazmanian, 2010
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, differential responsiveness of symptom dimensions coupled with the association of specific gene loci with behavioral symptoms suggests that distinct mechanisms may mediate the various aspects of cytokine-induced depression, and understanding these mechanisms may improve treatment strategies.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 2. Cytokines and depression > 2.6 Genetic vulnerability to exogenous cytokine-induced depression
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Therefore, it is reasonable that HPA-mediated vulnerability to cytokine-induced depression represents a more general hyper-responsiveness and pre-existing vulnerability to stress or inflammatory challenge, which may be mediated by changes in glucocorticoid receptor (GR) expression or function (Pace et al., 2007).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.2 Cytokine effects on neuropeptides and growth factors
What the sources say
- Not checked yetcites Pace et al., 2007 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Inflammatory cytokines activate IDO and KYN pathways in the brain that effect glutamate neurotransmission and may contribute to glutamate dysfunction in depression (McNally et al., 2008, Dantzer et al., 2011, Haroon et al., 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.3 Cytokine effects on glutamate neurotransmission
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Increased uptake and decreased turnover of FDOPA suggests a potential depletion of DA in DAergic terminals and increased synthetic capacity following IFN-alpha exposure.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Acutely, cytokines and immune activation increase locus coeruleus activity and NE release in the hippocampus and hypothalamus. This increase in NE activity is relevant to HPA-axis activation, fever, and metabolic change associated with immune activation (Dunn et al., 1999, Dunn et al., 2005).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Although inflammatory cytokines have been shown to induce GTP-cyclohydrolase I, the enzyme necessary for BH4 synthesis, inflammation-mediated. increases in ROS/RNS can oxidize BH4, whereas increased inducible NOS (iNOS) activity can usurp BH4 (see Figure 1), thus reducing it’s availability for DA synthesis (Cunnington and Channon, 2010).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Cunnington and Channon, 2010
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Monkeys that display huddling behavior in response to IFN-alpha have been found to exhibit significantly lower CSF concentrations of the dopamine metabolites, homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) (Felger et al., 2007, Felger and Miller, 2012), which correlated with reduced locomotor activity (Felger and Miller, 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Felger et al., 2007 source
- Not checked yetcites Felger and Miller, 2012
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Rhesus monkeys that express functional IFNARs and activate relevant signal transduction pathways in response to human IFN-alpha (Felger et al., 2007), exhibit immune, neuroendocrine, and behavioral responses to IFN-alpha similar to humans, including decreases in psychomotor activity and increases in depressive-like huddling behavior (in ~50% of animals) (Felger et al., 2007, Felger and Miller, 201”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Felger et al., 2007 source
- Not checked yetcites Felger and Miller, 2012
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Plasma Phen/Tyr ratios were increased in IFN-alpha-treated subjects compared to controls (Felger et al., 2012b, Zoller et al., 2012), and negatively correlated with CSF concentrations of DA and HVA, and positively correlated with fatigue, in IFN-alpha-treated patients (Felger et al., 2012b).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Felger et al., 2012b
- Not checked yetcites Zoller et al., 2012 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Furthermore, CSF concentrations of BH2 were significantly increased in IFN-alpha-treated patients compared to controls, and decreased CSF BH4 concentrations correlated with increased CSF IL-6 (Felger et al., 2012b).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Felger et al., 2012b
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Interestingly, both increased uptake and decreased turnover of FDOPA in the caudate, putamen and ventral striatum of IFN-alpha-treated patients was found (Capuron et al., 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
- Not checked yetcites Capuron et al., 2012 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Both KA and QUIN have been observed to be increased in the CSF of IFN-alpha-treated patients (Schwarcz and Pellicciari, 2002, Raison et al., 2010b), and CSF QUIN correlated with depressive symptoms during IFN-alpha administration (Raison et al., 2010b).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.3 Cytokine effects on glutamate neurotransmission
What the sources say
- Not checked yetcites Schwarcz and Pellicciari, 2002
- Not checked yetcites Raison et al., 2010b
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“IFN-alpha administration has also been found to decrease systemic BDNF levels in humans (Kenis et al., 2010, Lotrich et al., 2013) (see Figure 1), as can other inflammatory cytokines and LPS injections (Tong et al., 2008, Cortese et al., 2011) (Guan and Fang, 2006).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.2 Cytokine effects on neuropeptides and growth factors
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Inflammatory cytokines have repeatedly been observed to influence both neuronal development and apoptosis (Chawla-Sarkar et al., 2003, Hayley et al., 2005) (Mehler and Kessler, 1997, Zhao and Schwartz, 1998), (Peng et al., 2008, Anisman, 2009, Koo et al., 2010b). In fact, both stress and subsequent inflammatory cytokine activity may adversely influence neurogenesis and neuroplasticity (Patel et al”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.2 Cytokine effects on neuropeptides and growth factors
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In terms of the role of 5-HT in the treatment of cytokine-induced depression, SSRIs have been very effective in treating anxiety, depressed mood, and cognitive aspects of cytokine-induce depression, but not as effective for fatigue and neurovegetative symptoms (Capuron et al., 2002, Raison et al., 2005b, McNutt et al., 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“It is noteworthy that a direct comparison of the 5-HTTLPR and the met/val allele of BDNF found that the 5-HTTLPR Short allele was specifically associated with risk for neurovegetative symptoms of depression, while the BDNF Met allele was primarily associated with the cognitive symptoms (Lotrich et al., 2013).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.2 Cytokine effects on neuropeptides and growth factors
What the sources say
- Not checked yetcites Lotrich et al., 2013 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together, these data suggest that peripheral cytokine effects on basal ganglia function generalize to multiple inflammatory stimuli, and may be relevant to depression and specifically to symptoms of fatigue and psychomotor slowing.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The fatigue of depression, which is often a residual symptom of SSRI therapy, is a prominent feature of cytokine-induced depression, and may represent cytokine effects on the basal ganglia and dopamine (DA) function (Capuron et al., 2001, Majer et al., 2008, Capuron et al., 2009).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results indicate that inflammation is associated with decreased peripheral conversion of Phen to Tyr, which may in turn be associated with reduced DA in the brain as well as behavioral symptoms such as anhedonia and fatigue.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“MHPG has been examined in the CSF of IFN-alpha-treated patients but was not related to behavioral symptoms (Raison et al., 2009). SNPs of the gene for DA beta-hydroxylase, the enzyme that converts DA to NE, was examined in IFN-alpha-treated HCV+ subjects but was not associated with the development of depression (Smith et al., 2012).”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.1 Cytokine effects on the monoamines
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“baseline concentrations of circulating cytokines, such as IL-6, and markers of inflammation, like CRP, may be useful for indentifying subjects that will fail to respond to current antidepressant therapies”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 4. Translational and therapeutic implications > 4.1 Clinical significance and limitations
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“QUIN has been implicated in a number of neurodegenerative diseases, including Huntington’s disease, Amyotrophic Lateral Sclerosis, Alzheimer’s disease, and dementia secondary to infection with HIV”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.3 Cytokine effects on glutamate neurotransmission
What the sources say
- Not checked yetcites Schwarcz and Pellicciari, 2002
- Not checked yetcites Guidetti and Schwarcz, 2003
- Not checked yetcites Guillemin et al., 2005a
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“the mRNA specific adenosine deaminase 1 (ADAR1), which edits the AMPA glutamate receptor, is strongly induced by IFN-alpha”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.3 Cytokine effects on glutamate neurotransmission
What the sources say
- Not checked yetcites Liu and Samuel, 1999
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“persons with a history of childhood trauma tend to have higher inflammatory biomarkers as adults and also exhibit higher rates of depression”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 4. Translational and therapeutic implications > 4.1 Clinical significance and limitations
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“QUIN and inflammatory cytokines have also been shown to increase glutamate release and decrease the astrocytic uptake of glutamate by the excitatory amino acid transporter”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.3 Cytokine effects on glutamate neurotransmission
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus there are a variety of routes by which cytokines may influence the glutamatergic system and conceivably increase risk for depression.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.3 Cytokine effects on glutamate neurotransmission
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“thus making glutamate more available to extrasynaptic NMDARs and contributing to glutamate toxicity”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 3. Cytokine effects on neurotransmitter systems that may contribute to depression > 3.3 Cytokine effects on glutamate neurotransmission
What the sources say
- Not checked yetcites Hardingham et al., 2002 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Parkinson’s-like symptoms have been observed in some patients during IFN-alpha administration, and these symptoms have been successfully treated with levodopa”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 4. Translational and therapeutic implications > 4.2 Potential therapeutic strategies for treatment of cytokine-induced depression
What the sources say
- Not checked yetcites Mizoi et al., 1997
- Not checked yetcites Sarasombath et al., 2002
- Not checked yetcites Bersano et al., 2008 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“numerous biomarkers and gene polymorphisms that confer vulnerability to cytokine-induced depression have been indentified, and may be useful in identifying at-risk patients”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 5. Summary and conclusions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“IDO-deficient mice are resistant to behavioral changes following infection with bacille Calmette–Guerin (BCG), while showing a normal inflammatory cytokine response to BCG administration”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 4. Translational and therapeutic implications > 4.2 Potential therapeutic strategies for treatment of cytokine-induced depression
What the sources say
- Not checked yetcites O'Connor et al., 2009a
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“low serum folate has been associated with depression and with resistance to antidepressant treatment”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 4. Translational and therapeutic implications > 4.2 Potential therapeutic strategies for treatment of cytokine-induced depression
What the sources say
- Not checked yetcites Fava et al., 1997 source
- Not checked yetcites Papakostas et al., 2004a
- Not checked yetcites Gilbody et al., 2007a
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“inhibition of the NMDA receptor with memantine prevented the onset of DA deficits in the brains of SIV-infected macaques, and effect mediated by increased BDNF”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 4. Translational and therapeutic implications > 4.2 Potential therapeutic strategies for treatment of cytokine-induced depression
What the sources say
- Not checked yetcites Meisner et al., 2008 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Sapropterin (Kuvan) is the first non-dietary, FDA-approved, synthetic form of BH4 for patients with phenylketonuria that is effective in lowering blood Phen levels by stabilizing and increasing PAH activity”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 4. Translational and therapeutic implications > 4.2 Potential therapeutic strategies for treatment of cytokine-induced depression
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Peripheral cytokines can access the brain and activate local CNS inflammatory networks to produce alterations in neurotransmitter function.”
§ Inflammatory Cytokines in Depression: Neurobiological Mechanisms and Therapeutic Implications > 5. Summary and conclusions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
SSRIs and other classical antidepressants targeting the 5-HT system are efficacious for many aspects of major depression and cytokine-induced depression.
“Although SRRIs and other classical antidepressants that target the 5-HT system are efficacious in treating many aspects of both major depression and cytokine-induced depression”
The paper relies on this without support.
Knockout mice lacking the ATP P2X7 receptor, which stimulates inflammasome-mediated IL-1beta release, show an antidepressant-like profile with increased mobility in tail suspension and forced swim tests.
“knockout mice for the ATP P2X7 receptor that stimulates inflammasome-mediated IL-1beta release exhibit an antidepressant-like profile, including increased mobility in the tail suspension and forced swim tests”
The paper relies on this without support.
Classic stimulants increase dopamine release and block DAT function.
“Classic stimulants act to increase DA release and block DAT function”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Secretion of IL-1β, IL-6 and TNF-α with macrophage-associated proinflammatory cytokines was synchronized with M1 activation in MDD patients [15].”
From Neuron secrete exosomes containing miR-9-5p to promote polarization of M1 microglia in depression (2022) · cites this paper as [15]
Experimental — accuracy not yet measuredIn the citing paper
“It has been shown that chronic exposure to elevated inflammatory cytokines can lead to depression (108).”
From Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders (2018) · cites this paper as [108]
In the citing paper
“Growing evidence suggests that pro-inflammatory cytokines contribute to the pathogenesis of psychiatric diseases such as depression [137,138]”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [137]
In the citing paper
“The idea that stress itself induces endocrine mediators like IL6, which is traditionally associated with inflammation, has since been supported by the detection of increased circulating cytokines in depression and anxiety (Felger and Lotrich, 2013; Khandaker et al., 2014), and by the association of IL6 polymorphisms in individuals with depression (Zhang et al., 2016).”
From Origin and function of stress-induced IL-6 in murine models (2020) · cites this paper as Felger and Lotrich, 2013
Citations
Cites
Items 201–400 of 437
Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity
Gilbody, S. M., Lightfoot, T., & Sheldon, T. (2007) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2006.050385 · Cited by 251
Suarez, E. C. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.01.011 · Cited by 248
Guan, Z., & Fang, J. (2006) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2005.04.005 · Cited by 247
Capuron, L., Ravaud, A., Miller, A. H., & Dantzer, R. (2003) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2003.11.004 · Cited by 243
Khaodhiar, L., Ling, P., Blackburn, G. L., & Bistrian, B. R. (2004) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607104028006410 · Cited by 243
Shaftel, S. S., Carlson, T. J., Olschowka, J. A., Kyrkanides, S., Matousek, S. B., & O'Banion, M. K. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1418-07.2007 · Cited by 243
Sriram, K., Miller, D. B., & O'Callaghan, J. P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03566.x · Cited by 242 · cited 1×
“Moreover, microglial activation and inflammatory cytokines are associated with worse outcome following exposure to these compounds (Gao et al., 2002, Sriram et al., 2006).”
BackgroundBonaccorso, S., Puzella, A., Marino, V., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Levrero, M., Egyed, B., Bosmans, E., et al. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00315-8 · Cited by 235
Expression of The Kynurenine Pathway Enzymes in Human Microglia and Macrophages
Guillemin, G. J., Smith, D. G., Smythe, G. A., Armati, P. J., & Brew, G. J. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0135-0_12 · Cited by 229
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S., & Brunello, N. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200607000-00005 · Cited by 229
Basal Ganglia Hypermetabolism and Symptoms of Fatigue during Interferon-α Therapy
Capuron, L., Pagnoni, G., Demetrashvili, M. F., Lawson, D. H., Fornwalt, F. B., Woolwine, B., Berns, G. S., Nemeroff, C. B., & Miller, A. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301362 · Cited by 229
Entry of Blood-Borne Cytokines into the Central Nervous System: Effects on Cognitive Processes
Banks, W. A., Farr, S. A., & Morley, J. E. (2002) · NeuroImmunoModulation · doi:10.1159/000071472 · Cited by 228
Bufalino, C., Hepgul, N., Aguglia, E., & Pariante, C. M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.04.009 · Cited by 228
Zhu, C.-B., Carneiro, A. M., Dostmann, W. R., Hewlett, W. A., & Blakely, R. D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410858200 · Cited by 228
The phenomenology and treatment of interferon-induced depression
Loftis, J. M., & Hauser, P. (2004) · Journal of Affective Disorders · doi:10.1016/j.jad.2004.04.002 · Cited by 228
Bull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Behan, W. M. H., McDonald, M., Darlington, L. G., & Stone, T. W. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702940 · Cited by 225
Loberiza, F., Rizzo, J. D., Bredeson, C., Antin, J., Horowitz, M. M., Weeks, J. C., & Lee, S. J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.757 · Cited by 225
Interleukin-1β impairs brain derived neurotrophic factor-induced signal transduction
Tong, L., Balazs, R., Soiampornkul, R., Thangnipon, W., & Cotman, C. W. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.027 · Cited by 222
Fujigaki, H., Saito, K., Fujigaki, S., Takemura, M., Sudo, K., Ishiguro, H., & Seishima, M. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvj072 · Cited by 222
Katsuura, G., Arimura, A., Köves, K., & Gottschall, P. E. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.1.e163 · Cited by 220
The Portal Theory Supported by Venous Drainage–Selective Fat Transplantation
Rytka, J. M., Wueest, S., Schoenle, E. J., & Konrad, D. (2010) · Diabetes · doi:10.2337/db10-0697 · Cited by 217
Kruijshaar, M. E., Barendregt, J. J., Vos, T., de Graaf, R., Spijker, J., & Andrews, G. (2005) · European Journal of Epidemiology · doi:10.1007/s10654-004-1009-0 · Cited by 216
Pollak, Y., & Yirmiya, R. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003152 · Cited by 215
Butler, J. M., Case, L. D., Atkins, J., Frizzell, B., Sanders, G., Griffin, P., Lesser, G., McMullen, K., McQuellon, R., Naughton, M., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.05.076 · Cited by 214
Felger, J. C., Alagbe, O., Hu, F., Mook, D., Freeman, A. A., Sanchez, M. M., Kalin, N. H., Ratti, E., Nemeroff, C. B., & Miller, A. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.026 · Cited by 214
Self-citationStone, T. W. (2000) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01451-6 · Cited by 211
Selective Serotonin-Reuptake Inhibitors: An Update
Masand, P. S., & Gupta, S. (1999) · Harvard Review of Psychiatry · doi:10.3109/hrp.7.2.69 · Cited by 211
Protective Actions of the Vesicular Monoamine Transporter 2 (VMAT2) in Monoaminergic Neurons
Guillot, T. S., & Miller, G. W. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8059-y · Cited by 209
Cytokines, “depression due to a general medical condition”, and antidepressant drugs
Yirmiya, R., Weidenfeld, J., Pollak, Y., Morag, M., Morag, A., Avitsur, R., Barak, O., Reichenberg, A., Cohen, E., Shavit, Y., et al. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_16 · Cited by 208
Frontostriatal functional connectivity in major depressive disorder
Furman, D. J., Hamilton, J. P., & Gotlib, I. H. (2011) · Biology of Mood & Anxiety Disorders · doi:10.1186/2045-5380-1-11 · Cited by 208
Zhao, B., & Schwartz, J. P. (1998) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19980401)52:1 · Cited by 207
Fábry, Z., Fitzsimmons, K. M., Herlein, J. A., Moninger, T. O., Dobbs, M. B., & HART, M. N. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90281-3 · Cited by 207
Heim, C. C., Owens, M. J., Plotsky, P. M., & Nemeroff, C. B. (1997) · PubMed · Cited by 206
Depression, immunocompetence, and prostaglandins of the E series
Calabrese, J. R., Skwerer, R. G., Barna, B. P., Gulledge, A. D., Valenzuela, R., Butkus, A., Subichin, S., & Krupp, N. E. (1986) · Psychiatry Research · doi:10.1016/0165-1781(86)90040-5 · Cited by 205
Modafinil in treatment of fatigue in multiple sclerosis
Zifko, U., Rupp, M., Schwarz, S. C., Zipko, H. T., & Maida, E. M. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0765-6 · Cited by 203
Cao, C., Matsumura, K., Yamagata, K., & Watanabe, Y. (1997) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1997.272.6.r1712 · Cited by 203
Kunugi, H., Hori, H., Adachi, N., & Numakawa, T. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02135.x · Cited by 200
Localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain
Schöbitz, B., Voorhuis, D. A. M., & de Kloet, E. R. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90046-a · Cited by 200
Mechanisms of methamphetamine-induced dopaminergic neurotoxicity
Riddle, E. L., Fleckenstein, A. E., & Hanson, G. R. (2006) · The AAPS Journal · doi:10.1007/bf02854914 · Cited by 199
Fan, H. M., Clemons, M. J., Xu, W., Chemerynsky, I., Breunis, H., Braganza, S., & Tannock, I. F. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-007-0341-9 · Cited by 197
Trefz, F. K., Burton, B. K., Longo, N., Casanova, M. M.-P., Gruskin, D. J., Dorenbaum, A., Kakkis, E. D., Crombez, E. A., Grange, D. K., Harmatz, P., et al. (2009) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.11.040 · Cited by 196
de la Cruz, V. P., Carrillo-Mora, P. U., & Santamarı́a, A. (2012) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s8158 · Cited by 193
Dumitrescu, C., Biondi, R., Xia, Y., Cardounel, A. J., Druhan, L. J., Ambrosio, G., & Zweier, J. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702986104 · Cited by 192
QTL Analysis of Multiple Behavioral Measures of Anxiety in Mice
Henderson, N. D., Turri, M. G., DeFries, J. C., & Jonathan Flint, C. (2004) · Behavior Genetics · doi:10.1023/b:bege.0000017872.25069.44 · Cited by 192
Amantadine for fatigue in multiple sclerosis
Pucci, E., Tato, P. B., D’Amico, R., Giuliani, G., Solari, A., & Taus, C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002818.pub2 · Cited by 189
Resveratrol differentially modulates inflammatory responses of microglia and astrocytes
Lu, X., Ma, L., Ruan, L., Kong, Y., Mou, H., Zhang, Z., Wang, Z., Wang, J., & Le, Y. (2010) · Journal of Neuroinflammation · doi:10.1186/1742-2094-7-46 · Cited by 189
Raison, C. L., Borisov, A. S., Woolwine, B. J., Massung, B., Vogt, G., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.58 · Cited by 183
Monk, J. P., Phillips, G., Waite, R., Kuhn, J., Schaaf, L. J., Otterson, G. A., Guttridge, D., Rhoades, C., Shah, M., Criswell, T., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.2838 · Cited by 179
Willeit, M., Praschak-Rieder, N., Neumeister, A., Pirker, W., Asenbaum, S., Vitouch, O., Tauscher, J. T., Hilger, E., Stastny, J., Brücke, T., et al. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00293-0 · Cited by 178
Felger, J. C., Li, L., Marvar, P. J., Woolwine, B. J., Harrison, D. G., Raison, C. L., & Miller, A. H. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.10.010 · Cited by 176
Self-citationSong, C., Merali, Z., & Anisman, H. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00271-1 · Cited by 172
Tausk, F., Elenkov, I. J., & Moynihan, J. A. (2008) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2008.00166.x · Cited by 172
Pyrrolopyridine Inhibitors of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK-2)
Anderson, D. R., Meyers, M. J., Vernier, W. F., Mahoney, M. W., Kurumbail, R. G., Caspers, N. L., Poda, G. I., Schindler, J. F., Reitz, D. B., & Mourey, R. J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0611004 · Cited by 171
Lestage, J., Verrier, D., Palin, K., & Dantzer, R. (2002) · Brain, Behavior, and Immunity · doi:10.1016/s0889-1591(02)00014-4 · Cited by 170
Su, K., Huang, S., Peng, C., Lai, H., Huang, C., Chen, Y.-C., Aitchison, K. J., & Pariante, C. M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.005 · Cited by 170
Capuron, L., Fornwalt, F. B., Knight, B. T., Harvey, P. D., Ninan, P. T., & Miller, A. H. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.017 · Cited by 164
Treatment-Resistant Depression and Mortality After Acute Coronary Syndrome
Carney, R. M., & Freedland, K. E. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08081239 · Cited by 163 · cited 1×
“…and acute-phase proteins than patients who respond to antidepressant treatment (Sluzewska et al., 1997, Lanquillon et al., 2000, Fitzgerald et al., 2006), and are at even greater risk of morbidity and mortality in medical illness such as coronary heart disease (Carney and Freedland, 2009).”
BackgroundOmega-3 Fatty Acid Augmentation of Citalopram Treatment for Patients With Major Depressive Disorder
Gertsik, L., Poland, R. E., Bresee, C., & Rapaport, M. H. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31823f3b5f · Cited by 162
Greenberg, D. B., Gray, J. L., Mannix, C. M., Eisenthal, S., & Carey, M. (1993) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(93)90127-h · Cited by 160
Hematolymphopoietic and inflammatory cytokines in neural development
Mehler, M. F., & Kessler, J. A. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)01045-4 · Cited by 160
Morikawa, O., Sakai, N., Obara, H., & Saito, N. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00187-3 · Cited by 160
Maslanik, T., Mahaffey, L., Tannura, K., Beninson, L., Greenwood, B. N., & Fleshner, M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.10.014 · Cited by 156
The Endocannabinoid System and the Treatment of Mood and Anxiety Disorders
Hill, M. N., & Gorzalka, B. B. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824624 · Cited by 155
Moraska, A. R., Sood, A., Dakhil, S., Sloan, J., Barton, D., Atherton, P., Suh, J. J., Griffin, P. C., Johnson, D. B. F., Ali, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1444 · Cited by 154
Kaneko, N., Kudo, K., Mabuchi, T., Takemoto, K., Fujimaki, K., Wati, H., Iguchi, H., Tezuka, H., & Kanba, S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301137 · Cited by 152
Repeated interferon-α administration inhibits dopaminergic neural activity in the mouse brain
Shuto, H., Kataoka, Y., Horikawa, T., Fujihara, N., & Oishi, R. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01371-6 · Cited by 151
Lopresti, A. L., Hood, S. D., & Drummond, P. D. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112458732 · Cited by 151
Liu, Z., Zhu, F., Wang, G., Xiao, Z., Tang, J., Liu, W., Wang, H., Liu, H., Wang, X., Ying-liang, W., et al. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.12.013 · Cited by 151
Kynurenic acid leads, dopamine follows: A new case of volume transmission in the brain?
Wu, H., Rassoulpour, A., & Schwarcz, R. M. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0562-y · Cited by 151
CSF Prostaglandin Levels in Depressed and Schizophrenic Patients
Linnoila, M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790040059008 · Cited by 150
Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α
PEMBERTON, L. A., KERR, S. J., SMYTHE, G., & BREW, B. J. (1997) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1997.17.589 · Cited by 149
Glutamate and ATP signalling in white matter pathology
Matute, C. (2011) · Journal of Anatomy · doi:10.1111/j.1469-7580.2010.01339.x · Cited by 149
Capuron, L., Ravaud, A., & Dantzer, R. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200105000-00007 · Cited by 148
Guo, J.-Y., Li, C.-Y., Ruan, Y.-P., Sun, M., Qi, X.-L., Zhao, B.-S., & Luo, F. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.076 · Cited by 148
Kitagami, T., Yamada, K., Miura, H., Hashimoto, R., Nabeshima, T., & Ohta, T. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02776-8 · Cited by 147
Kaasinen, V. (2001) · Brain · doi:10.1093/brain/124.6.1125 · Cited by 147
Peng, C., Chiou, S., Chen, S., Chou, Y., Ku, H., Cheng, C., Yen, C.-J., Tsai, T., Chang, Y., & Kao, C.-L. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2007.05.002 · Cited by 145
RAISON, C. L., WOOLWINE, B. J., DEMETRASHVILI, M. F., BORISOV, A. S., WEINREIB, R., STAAB, J. P., ZAJECKA, J. M., BRUNO, C. J., HENDERSON, M. A., REINUS, J. F., et al. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03316.x · Cited by 142
Elevated levels of prostaglandin e2 and thromboxane B2 in depression
Lieb, J., Karmali, R. A., & Horrobin, D. F. (1983) · Prostaglandins Leukotrienes and Medicine · doi:10.1016/0262-1746(83)90048-3 · Cited by 142
Interleukin‐1 in the Brain: Mechanisms of Action in Acute Neurodegeneration
PATEL, H. C., BOUTIN, H., & ALLAN, S. M. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb03136.x · Cited by 139
Teeling, J. L., Cunningham, C., Newman, T. A., & Perry, V. H. (2010) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2009.11.006 · Cited by 139
Biomarkers of depression in cancer patients
Jehn, C. F., Kuehnhardt, D., Bartholomae, A., Pfeiffer, S., Krebs, M., Regierer, A. C., Schmid, P., Possinger, K., & Flath, B. C. (2006) · Cancer · doi:10.1002/cncr.22294 · Cited by 139
Cytokine-induced depression during IFN-α treatment: The role of IL-6 and sleep quality
Prather, A. A., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2009) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2009.07.001 · Cited by 139
Self-citationCurran, B. P., & O'Connor, J. J. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00405-5 · Cited by 138
Increased level of salivary prostaglandins in patients with major depression
Ohishi, K., Ueno, R., Nishino, S., Sakai, T., & Hayaishi, O. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90283-1 · Cited by 138
PET Studies of Cerebral Levodopa Metabolism: A Review of Clinical Findings and Modeling Approaches
Kumakura, Y., & Cumming, P. D. (2009) · The Neuroscientist · doi:10.1177/1073858409338217 · Cited by 136
Mentis, M. J., McIntosh, A. R., Perrine, K., Dhawan, V., Berlin, B., Feigin, A., Edwards, C., Mattis, P., & Eidelberg, D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.746 · Cited by 136
Lotrich, F. E., Ferrell, R. E., Rabinovitz, M., & Pollock, B. G. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.08.009 · Cited by 135
Self-citationGuillemin, G. J., Wang, L. H.-C., & Brew, B. J. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-16 · Cited by 135
Neurauter, G., Grahmann, A. V., Klieber, M., Zeimet, A. G., Ledochowski, M., Sperner‐Unterweger, B., & Fuchs, D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.07.002 · Cited by 134
Sluzewska, A., Sobieska, M., & Rybakowski, J. K. (2008) · Neuropsychobiology · doi:10.1159/000119332 · Cited by 134
Ferris, M. J., Mactutus, C. F., & Booze, R. M. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.01.004 · Cited by 133
Martinez, J. M., Garakani, A., Yehuda, R., & Gorman, J. M. (2012) · Depression and Anxiety · doi:10.1002/da.20876 · Cited by 131
Mößner, R. (1998) · Neurochemistry International · doi:10.1016/s0197-0186(98)00026-6 · Cited by 130
Coogan, A. N., O'Neill, L. A. J., & O'Connor, J. J. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00100-1 · Cited by 129
Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia.
Rottenberg, D. A., Sidtis, J. J., Strother, S. C., Schaper, K. A., Anderson, J., Nelson, M. J., & Price, R. W. (1996) · PubMed · Cited by 129
Fleshner, M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.08.012 · Cited by 126
Majer, M., Welberg, L. A. M., Capuron, L., Pagnoni, G., Raison, C. L., & Miller, A. H. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.12.009 · Cited by 124
Shah, A. J. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.125 · Cited by 124
Lim, W., Hong, S., Nelesen, R. A., & Dimsdale, J. E. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.8.910 · Cited by 123
Moldofsky, H. (1995) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(95)00051-3 · Cited by 121
Nichol, C. A., Lee, C. L., EDELSTEIN, M. P., Chao, J. Y., & Duch, D. S. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.6.1546 · Cited by 120
Nadjar, A., Bluthé, R.-M., May, M. J., Dantzer, R., & Parnet, P. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300755 · Cited by 120
Cortese, G. P., Barrientos, R. M., Maier, S. F., & Patterson, S. L. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5818-10.2011 · Cited by 120
Masilamoni, G. J., Bogenpohl, J. W., Alagille, D., Delevich, K. M., Tamagnan, G. D., Votaw, J. R., Wichmann, T., & Smith, Y. (2011) · Brain · doi:10.1093/brain/awr137 · Cited by 118
Wichers, M., Kenis, G., Koek, G. H., Robaeys, G., Nicolson, N. A., & Maes, M. H. J. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2006.09.007 · Cited by 117
Jazayeri, S., Keshavarz, S. A., Tehrani-Doost, M., Djalali, M., Hosseini, M., Amini, H., Chamari, M., & Djazayery, A. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.04.013 · Cited by 116
Sarchiapone, M., Carli, V., Roy, A., Iacoviello, L., Cuomo, C., Latella, M. C., di Giannantonio, M., Janiri, L., de Gaetano, M., & Janal, M. N. (2008) · Neuropsychobiology · doi:10.1159/000142361 · Cited by 115
The Relationship Between Cerebrospinal Fluid Biomarkers and Depression in Elderly Women
Gudmundsson, P., Skoog, I. G., Wærn, M., Blennow, K., Palsson, S. P., Rosengren, L., & Gustafson, D. (2007) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180547091 · Cited by 114
Kim, B., Jeong, H., Kim, J.-H., Lee, S. Y., Jou, I., & Joe, E.-H. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1000212 · Cited by 114
Papakostas, G. I., Petersen, T., Mischoulon, D., Ryan, J. L., Nierenberg, A. A., Bottiglieri, T., Rosenbaum, J. F., Alpert, J. E., & Fava, M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0810 · Cited by 113
Antidepressant-like actions of minocycline combined with several glutamate antagonists
Molina-Hernández, M., Téllez-Alcántara, N. P., Pérez-García, J., Olivera-Lopez, J. I., & Jaramillo, M. T. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.004 · Cited by 113
Depression, Anhedonia, and Psychomotor Symptoms:The Role of Dopaminergic Neurocircuitry
Stein, D. J. (2008) · CNS Spectrums · doi:10.1017/s1092852900016837 · Cited by 112
Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?
McNamara, R. K., & Lotrich, F. E. (2012) · Expert Review of Neurotherapeutics · doi:10.1586/ern.12.98 · Cited by 112
Self-citationDonnelly‐Roberts, D. L., Namovic, M. T., Surber, B. W., Vaidyanathan, S. X., Perez‐Medrano, A., Wang, Y., Carroll, W. A., & Jarvis, M. F. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.012 · Cited by 111
Dendritic Cells, Indoleamine 2,3 Dioxygenase and Acquired Immune Privilege
Huang, L., Baban, B., Johnson, B. A., & Mellor, A. L. (2010) · International Reviews of Immunology · doi:10.3109/08830180903349669 · Cited by 111
Depression in the medical setting: biopsychological interactions and treatment considerations.
Evans, D. L., Staab, J. P., Petitto, J. M., Morrison, M. F., Szuba, M. P., Ward, H. E., Wingate, B. J., Luber, M. P., & O’Reardon, J. P. (1999) · PubMed · Cited by 108
Does minocycline have antidepressant effect?
Pae, C., Marks, D. M., Han, C., & Patkar, A. A. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2007.12.005 · Cited by 108
Ida, T., Hara, M., Nakamura, Y., Kozaki, S., Tsunoda, S., & Ihara, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2007.12.047 · Cited by 107
Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders
Manki, H., Kanba, S., Muramatsu, T., Higuchi, S., Suzuki, E., Matsushita, S., Ono, Y., Chiba, H., Shintani, F., Nakamura, M., et al. (1996) · Journal of Affective Disorders · doi:10.1016/0165-0327(96)00035-3 · Cited by 106
Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis
Guillemin, G. J., Meininger, V., & Brew, B. J. (2005) · Neurodegenerative Diseases · doi:10.1159/000089622 · Cited by 105 · cited 2×
“…pathway by which cytokines may mediate behavioral effects is by activation of IDO (Pemberton et al., 1997, Fujigaki et al., 2006), an enzyme expressed in multiple cell types, including macrophages, dendritic cells, microglia, astrocytes, and neurons (Guillemin et al., 2005c, Huang et al., 2010).”
BackgroundKamata, M. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(99)00067-x · Cited by 105
Immunobiology of the blood-brain barrier
Miller, D. W. (1999) · Journal of NeuroVirology · doi:10.3109/13550289909021286 · Cited by 105
Prostaglandins mediate depressive-like behaviour induced by endotoxin in mice
de Paiva, V. N., Lima, S. N. P., Fernandes, M. M., Soncini, R., Andrade, C. A. F., & Giusti-Paiva, A. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.07.015 · Cited by 104 · cited 1×
“…behaviors, including decreased sucrose preference, increased immobility in tail suspension and forced swim, and decreased activity in open field tests, in laboratory animals induced by LPS and chronic unpredictable stress (Guo et al., 2009, de Paiva et al., 2010, Teeling et al., 2010).”
BackgroundKraus, M. R., Al‐Taie, O., Schäfer, A., Pfersdorff, M., Lesch, K., & Scheurlen, M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.02.053 · Cited by 104
Enhancement of recovery from psychiatric illness by methylfolate
Godfrey, P. M., Crellin, R. F., Toone, B., Flynn, T., Carney, M. W. P., Laundy, M., Chanarin, I., Bottiglieri, T., & Reynolds, E. H. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.161.1.126 · Cited by 99
Systemic interferon-α regulates interferon-stimulated genes in the central nervous system
Wang, J., Campbell, I. L., & Zhang, H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002013 · Cited by 99
Lalancette–Hébert, M., Julien, C., Cordeau, P., Bohaček, I., Weng, Y.-C., Calon, F., & Križ, J. (2011) · Stroke · doi:10.1161/strokeaha.111.620856 · Cited by 98
Haeffel, G. J., Getchell, M., Koposov, R. A., Yrigollen, C. M., De Young, C. G., Klinteberg, B. A., Oreland, L., Ruchkin, V. V., & Grigorenko, E. L. (2008) · Psychological Science · doi:10.1111/j.1467-9280.2008.02047.x · Cited by 96
Interaction between genetic polymorphisms and stressful life events in first episode depression
Bukh, J. D., Bock, C., Vinberg, M., Werge, T. M., Gether, U., & Kessing, L. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.02.023 · Cited by 93
Lotrich, F. E., Sears, B., & McNamara, R. K. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.08.007 · Cited by 92
Self-citationLotrich, F. E., Albusaysi, S., & Ferrell, R. E. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.263 · Cited by 92
Self-citationMaes, M. H. J., Gałecki, P., Verkerk, R. M., & Rief, W. (2011) · PubMed · Cited by 89
Wojna, V., Skolasky, R. L., Hechavarría, R., Mayo, R., Selnes, O. A., McArthur, J. C., Meléndez, L. M., Maldonado, E., Zorrilla, C., García, H., et al. (2006) · Journal of NeuroVirology · doi:10.1080/13550280600964576 · Cited by 89
The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide
Pregelj, P., Nedic, G., Paska, A. V., Zupanc, T., Nikolac, M., Balažic, J., Tomori, M., Komel, R., Seler, D. M., & Pivac, N. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.07.001 · Cited by 88
Salivary prostaglandin concentrations: possible state indicators for major depression
Nishino, S., Ueno, R., Ohishi, K., Sakai, T., & Hayaishi, O. (1989) · American Journal of Psychiatry · doi:10.1176/ajp.146.3.365 · Cited by 88
Signaling the brain in inflammation: the role of endothelial cells
Matsumura, K. (2004) · Frontiers in bioscience · doi:10.2741/1439 · Cited by 87
Karg, K., Burmeister, M., Shedden, K., & Sen, S. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.189 · Cited by 87
Palma, J. P., Kwon, D., Clipstone, N. A., & Kim, B. (2003) · Journal of Virology · doi:10.1128/jvi.77.11.6322-6331.2003 · Cited by 85
Smith, A. K., Simon, J. S., Gustafson, E. L., Noviello, S., Cubells, J. F., Epstein, M. P., Devlin, D. J., Qiu, P., Albrecht, J. K., Brass, C. A., et al. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.67 · Cited by 84 · cited 9×
“HCV+ subjects and also did not associate with cytokine-induced depression (Smith et al., 2012).”
BackgroundMethodResultInfluentialKanellopoulos, D., Gunning, F. M., Morimoto, S. S., Hoptman, M. J., Murphy, C. F., Kelly, R. E., Glatt, C. E., Lim, K. O., & Alexopoulos, G. S. (2010) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181f61d62 · Cited by 81
Yates, W. R., & Gleason, O. C. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:4 · Cited by 81
Oscillations in the basal ganglia
Wichmann, T., & DeLong, M. R. (1999) · Nature · doi:10.1038/23148 · Cited by 80
Heritability of individual depressive symptoms
Jang, K. L., Livesley, W. J., Taylor, S. J., Stein, M. B., & Moon, E. C. (2003) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00108-3 · Cited by 80
Fatigue as a residual symptom of depression.
Targum, S. D., & D, M. F. M. (2011) · PubMed Central · Cited by 76
Sun, S., Xia, S., Ji, Y., Kersten, S., & Qi, L. (2012) · Diabetes · doi:10.2337/db11-1389 · Cited by 76
for the German Competence Network HIV/AIDS, Meisner, F., Scheller, C., Kneitz, S., Sopper, S., Neuen-Jacob, E., Riederer, P., Meulen, V. T., & Koutsilieri, E. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301615 · Cited by 73
The Role of Cytokines in Infection‐Related Behaviora
Dunn, A. J., & Swiergiel, A. H. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09596.x · Cited by 73
Ropinirole in treatment-resistant depression: a 16-week pilot study
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000612 · Cited by 73
Serum Folate, Vitamin B12, and Homocysteine in Major Depressive Disorder, Part 2
Papakostas, G. I., Petersen, T., Mischoulon, D., Green, C. H., Nierenberg, A. A., Bottiglieri, T., Rosenbaum, J. F., Alpert, J. E., & D, M. F. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0811 · Cited by 72
Godbout, J. P., Berg, B. M., Krzyszton, C. P., & Johnson, R. W. (2005) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2005.08.003 · Cited by 72
Major depression during interferon-α treatment: vulnerability and prevention
Lotrich, F. E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.4/felotrich · Cited by 72
Self-citationStahl, S. M. (2007) · CNS Spectrums · doi:10.1017/s1092852900015418 · Cited by 71
Gelman, B. B., Spencer, J. A., Holzer, C. E., & Soukup, V. M. (2006) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-006-9030-6 · Cited by 68
Liu, Y., & Samuel, C. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.5070 · Cited by 68
Zhang, J., Terreni, L., Simoni, M. G. D., & Dunn, A. J. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(00)00099-1 · Cited by 67
Indicators of immune activation in depressed patients
Sluzewska, A. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_4 · Cited by 66
FITZGERALD, P., O'BRIEN, S. M., SCULLY, P., RIJKERS, K., SCOTT, L. V., & DINAN, T. G. (2006) · Psychological Medicine · doi:10.1017/s003329170500632x · Cited by 66
Interactions of Cytokines with the Blood-Brain Barrier: Implications for Feeding
Pan, W., & Kastin, A. J. (2003) · Current Pharmaceutical Design · doi:10.2174/1381612033455332 · Cited by 65
Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study
Sugawara, Y., Akechi, T., Shima, Y., Okuyama, T., Akizuki, N., Nakano, T., & Uchitomi, Y. (2002) · Palliative Medicine · doi:10.1191/0269216302pm547xx · Cited by 64
Garza, R. D. L., & Asnis, G. M. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02757-4 · Cited by 64
Burton, B. K., Bausell, H., Katz, R., LaDuca, H., & Sullivan, C. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.06.015 · Cited by 62
In vivo quinolinic acid increases synaptosomal glutamate release in rats: reversal by guanosine
Tavares, R. G., Schmidt, A. P., Abud, J., Tasca, C. I., & Souza, D. O. (2005) · Neurochemical Research · doi:10.1007/s11064-005-2678-0 · Cited by 59
3-Hydroxykynurenine and Quinolinate: Pathogenic Synergism in Early Grade Huntington’s Disease?
Guidetti, P., & Schwarcz, R. M. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0135-0_16 · Cited by 58
Kenis, G., Prickaerts, J., van Os, J., Koek, G. H., Robaeys, G., Steinbusch, H. W. M., & Wichers, M. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000830 · Cited by 58
McNutt, M. D., Liu, S., Manatunga, A., Royster, E. B., Raison, C. L., Woolwine, B. J., Demetrashvili, M. F., Miller, A. H., & Musselman, D. L. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.330 · Cited by 56
Kazumori, H., Ishihara, S., Rumi, M. A. K., Ortega-Cava, C. F., Kadowaki, Y., & Kinoshita, Y. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00269.2003 · Cited by 56
Felger, J. C., Cole, S. W., Pace, T. W. W., Hu, F., Woolwine, B. J., Doho, G., Raison, C. L., & Miller, A. H. (2011) · Psychological Medicine · doi:10.1017/s0033291711002868 · Cited by 56
Self-citationGinsberg, L. D., Oubré, A., & Daoud, Y. (2011) · PubMed Central · Cited by 55
Inflammatory Cytokines, Growth Factors, and Depression
Lotrich, F. E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523680 · Cited by 55
Self-citationMaddock, C., Landau, S., Barry, K., Maulayah, P., Hotopf, M., Cleare, A. J., Norris, S., & Pariante, C. M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001634 · Cited by 54
Sánchez, M. M., Alagbe, O., Felger, J. C., Zhang, J., Graff, A., Grand, A. P., Maestripieri, D., & Miller, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002025 · Cited by 54
Self-citationEffects of Chronic Administration of Interferon α A/D on Serotonergic Receptors in Rat Brain
Abe, S., Hori, T., Suzuki, T., Baba, A., Shiraishi, H., & Yamamoto, T. (1999) · Neurochemical Research · doi:10.1023/a:1020929415443 · Cited by 53
Loftis, J. M., Patterson, A. L., Wilhelm, C., McNett, H., Morasco, B. J., Huckans, M. S., Morgan, T. R. M., Saperstein, S., Asghar, A., & Hauser, P. (2012) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.10.012 · Cited by 53
The treatment of psoriasis with IL-10: rationale and review of the first clinical trials
Asadullah, K., Döcke, W., Sabat, R., Volk, H., & Sterry, W. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.1.95 · Cited by 52
Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology
Cunnington, C., & Channon, K. M. (2010) · Heart · doi:10.1136/hrt.2009.180430 · Cited by 52
Inhibitors of the kynurenine pathway
Stone, T. W. (2000) · European Journal of Medicinal Chemistry · doi:10.1016/s0223-5234(00)00121-5 · Cited by 52
Tsao, C. ‐., Lin, Y.-S., Cheng, J.-T., Lin, C.-F., Wu, H., Wu, S. ‐., & Tsai, W.-H. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107082951 · Cited by 51
Clement, H. W., Buschmann, J., Rex, S., Grote, C., Opper, C., Gemsa, D., & Wesemann, W. (1997) · Journal of Neural Transmission · doi:10.1007/bf01273312 · Cited by 50
Utz, J. R. J., Lorentz, C. P., Markowitz, D., Rudser, K. D., Diethelm-Okita, B., Erickson, D., & Whitley, C. B. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.10.014 · Cited by 48
Zhang, L., Fang, Y., Zeng, Z., Lian, Y., Wei, J., Zhu, H., Jia, Y., Zhao, X., & Xu, Y. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110113 · Cited by 47
Su, N., Zhang, L., Fei, F., Hu, H., Wang, K., Hui, H., Jiang, X., Li, X., Zhen, H., Li, J., et al. (2011) · Brain Research · doi:10.1016/j.brainres.2011.08.005 · Cited by 47
The Role of Pro-inflammatory Cytokines in Memory Processes and Neural Plasticity
Goshen, I., & Yirmiya, R. (2007) · Elsevier eBooks · doi:10.1016/b978-012088576-3/50021-6 · Cited by 47
Weiner, J. A., & Chun, J. J. M. (1997) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19970505)381:2 · Cited by 46
Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression
Oxenkrug, G. F., Perianayagam, M. C., Mikolich, D., REQUINTINA, P. J., Shick, L., Ruthazer, R., Zucker, D. R., & D, P. S. M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0525-1 · Cited by 46
Collins, J. M., Riccardi, R., Trown, P. W., O’Neill, D. L., & Poplack, D. G. (1985) · Cancer Drug Delivery · doi:10.1089/cdd.1985.2.247 · Cited by 44
Constitutive Expression of Interleukin-1beta (IL-1beta) in Rat Oligodendrocytes
Blasi, F., Riccio, M., Brogi, A., Strazza, M., Taddei, L., Romagnoli, S., Luddi, A., D’Angelo, R., Santi, S., Costantino‐Ceccarini, E., et al. (1999) · Biological Chemistry · doi:10.1515/bc.1999.034 · Cited by 43
Fahey, B., Hickey, B., Kelleher, D., O’Dwyer, A.-M., & O’Mara, S. M. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.05.005 · Cited by 43 · cited 2×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript behavior without affecting BDNF levels (Fahey et al., 2007).”
BackgroundLu, D., Leung, Y., & Su, K. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000338 · Cited by 43
Lotrich, F. E., Ferrell, R. E., Rabinovitz, M., & Pollock, B. G. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181de8966 · Cited by 42
Self-citationLotrich, F. E., Pollock, B. G., Kirshner, M. A., Ferrell, R. F., & Reynolds, C. F. (2008) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0814 · Cited by 42
Self-citationEffects of reserpine on the social behavior of rhesus monkeys.
Wt, M., Rg, E., Ec, M., Sj, S., & Harlow, H. F. (1971) · PubMed · Cited by 42
Felger, J. C., Alagbe, O., Pace, T. W. W., Woolwine, B. J., Hu, F., Raison, C. L., & Miller, A. H. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.02.015 · Cited by 41 · cited 1×
“Increased p38 MAPK activation (phosphorylation) in lymphocytes following the initial injection of IFN-alpha has predicted IFN-alpha-induced depression and fatigue in HCV+ patients (Felger et al., 2011).”
BackgroundSelf-citationSissolak, G., Hoffbrand, A. V., Mehta, A. B., & GANESHAGURU, K. (1992) · PubMed · Cited by 41
Effect of interferon-α on tyrosine hydroxylase and catecholamine levels in the brain of rats
Kumai, T., Tateishi, T., Tanaka, M., WATANABÉ, M., Shimizu, H., & Kobayashi, S. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00660-3 · Cited by 40
Pariante, C. M., Pearce, B. D., Pisell, T. L., Sanchez, C. I., Po, C., Su, C., & Miller, A. H. (1999) · Endocrinology · doi:10.1210/en.140.9.4359 · Cited by 40
Observational studies of dopamine D1 and D2 agonists in squirrel monkeys
Rosenzweig-Lipson, S. J., Hesterberg, P. E., & Bergman, J. (1994) · Psychopharmacology · doi:10.1007/bf02244865 · Cited by 38
Shimizu, H., Ohtani, K.-I., SATO, N., Nagamine, T., & Mori, M. (1995) · Endocrine Journal · doi:10.1507/endocrj.42.551 · Cited by 38
Higher zinc intake buffers the impact of stress on depressive symptoms in pregnancy
Roy, A., Evers, S. E., Avison, W. R., & Campbell, M. K. (2010) · Nutrition Research · doi:10.1016/j.nutres.2010.09.011 · Cited by 37
Flagged first, then by citations
8 of the 445 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Capuron, 2011, Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms, Biol Psychiatry, 70, 175, 10.1016/j.biopsych.2010.12.006 · DOI · Paper page
- Koo, 2010, Nuclear factor-kb is a critical mediator of stress-impaired neurogenesis and depressive behavior, Proc Natl Acad Sci U.., 107, 2669, 10.1073/pnas.0910658107 · DOI · Paper page
- O’Connor, 2009, Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice, Mol Psychiatry, 14, 511, 10.1038/sj.mp.4002148 · DOI · Paper page
- Zhu, 2010, Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters, Neuropsychopharmacology, 35, 2510, 10.1038/npp.2010.116 · DOI · Paper page
Cited by
Sorted by citations
The Lancet Commission on global mental health and sustainable development
Patel, V., Saxena, S., Lund, C., Thornicroft, G., Baingana, F., Bolton, P., Chisholm, D., Collins, P. Y., Cooper, J. L., Eaton, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31612-x · Cited by 3,692
Vagus Nerve as Modulator of the Brain–Gut Axis in Psychiatric and Inflammatory Disorders
Breit, S., Kupferberg, A., Rogler, G., & Hasler, G. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00044 · Cited by 1,189
“It has been shown that chronic exposure to elevated inflammatory cytokines can lead to depression (108).”
BackgroundNrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease
Ngo, V., & Duennwald, M. L. (2022) · Antioxidants · doi:10.3390/antiox11122345 · Cited by 1,130
Psychobiotics and the manipulation of bacteria–gut–brain signals
Sarkar, A., Lehto, S. M., Harty, S., Dinan, T. G., Cryan, J. F., & Burnet, P. W. J. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.09.002 · Cited by 1,068
The neurobiology of depression: An integrated view
Dean, J., & Keshavan, M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.025 · Cited by 765
Metadata
- Authors
- Felger, J. C., & Lotrich, F. E.
- Affiliations
- Emory University (US)
- University of Pittsburgh (US)
- ORCID
- Felger, J.C.
- Venue
- Neuroscience
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 246
- Pages
- 199-229
- ISSN
- 0306-4522 (ISSN-L)
- PMC
- PMC3741070
- OpenAlex
- W2004243143
- Cited by
- 1,180
- References
- 445
- Citations by year
- 2026: 97 · 2025: 125 · 2024: 99 · 2023: 98 · 2022: 127 · 2021: 107 · 2020: 86 · 2019: 104 · 2018: 101 · 2017: 70 · 2016: 60 · 2015: 61 · 2014: 31 · 2013: 12
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIMH (R090250)
- the Glenn Family Breast Fund
- the Winship Cancer Institute
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- inflammatory cytokines, depression, neuroinflammation, innate immune system, monoaminergic systems, glutamatergic system, neuropeptides, brain-derived neurotrophic factor, genetic polymorphism, childhood trauma, obesity, stress, sleep, neurotransmitter systems, cytokine signaling, anti-inflammatory therapy
- MeSH terms
- Animals, Antidepressive Agents, Brain, Depression, Humans, Inflammation, Biomarkers, Cytokines, Inflammation Mediators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
